The cortical damage, early relapses, and onset of the progressive phase in multiple sclerosis
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received October 6, 2017
- Accepted in final form April 2, 2018
- First Published May 16, 2018.
Article Versions
- Previous version (May 16, 2018 - 12:50).
- You are viewing the most recent version of this article.
Author Disclosures
- Antonio Scalfari, MD,
- Chiara Romualdi, PhD,
- Richard S. Nicholas, MD,
- Miriam Mattoscio, MD,
- Roberta Magliozzi, PhD,
- Aldo Morra, MD,
- Salvatore Monaco, MD,
- Paolo A. Muraro, MD and
- Massimiliano Calabrese, MD
- Antonio Scalfari, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Italian Multiple Sclerosis Foundation (FISM)
NONE
NONE
NONE
NONE
NONE
NONE
- Chiara Romualdi, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Richard S. Nicholas, MD,
(1) Biogen (2) Roche (3) Novartis (4) Genzyme
NONE
(1) Biogen
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Multiple Sclerosis Society/GE FAST FORWARD GRANT
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Miriam Mattoscio, MD,
(1) FISM, Italian Multiple Sclerosis Foundation, Scientific Committee Member
NONE
(1) Biogen Idec, Industry-funded travel (2) Teva, Industry-funded travel (3) Genzyme, Industry-funded travel (4) Merk Serono, Industry-funded travel and speaker honoraria (5) Novartis, Industry-funded travel and speaker honoraria
NONE
NONE
NONE
NONE
(1)Multiple Sclerosis Clinical Trial Collaboration (MSCT), consulting in the role of co-investigator/assessor neurologist
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Roberta Magliozzi, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Aldo Morra, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Salvatore Monaco, MD,
NONE
NONE
NONE
Journal of Alzheimer's Disease Neurological Sciences
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Paolo A. Muraro, MD and
NONE
NONE
Dr. Muraro has received travel support and speaker honoraria from Novartis, Bayer HealthCare, Bayer Pharma, Biogen Idec, Merck-Serono and Sanofi Aventis.
Academic Editor, PLOS Medicine.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Funder: Medical Research Council Type of grant: Project Grant Title: Pathfinder: An experimental medicine study of the 18 kD translocator protein as a novel neuroimmunodulatory target for multiple sclerosis Duration: 3 years 2016-19
NONE
Funder: UK Multiple Sclerosis Society / UK Stem Cell Foundation Type of grant: Collaborative Project Grant Title: A phase II trial of autologous mesenchymal stem cell transplantation in highly active multiple sclerosis ? Duration:2012-17 Funder: Italian Multiple Sclerosis Society Type of grant: Research Grant Title: EBV and autoreactivity in MS Duration:2016-18 PI: Muraro
NONE
NONE
NONE
NONE
NONE
NONE
- Massimiliano Calabrese, MD
Scientific advisory boards of Sanofi-Aventis, Merck Serono, Biogen Idec
NONE
Funding for travel from Sanofi-Aventis, Merk Serono, Biogen Idec, Bayer Schering Pharma
NONE
NONE
NONE
NONE
Sanofi Aventis La Roche
Sanofi-Aventis, Merk Serono, Biogen Idec, Bayer Schering Pharma
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Division of Neuroscience (A.S., R.S.N., M.M., P.M.), Imperial College, London, UK; Biology Department (C.R.), University of Padua; Department of Neurological, Biomedicine and Movement Sciences (R.M., S.M., M.C.), University of Verona; and Neuroradiology Unit (A.M.), Euganea Medica, Padua, Italy.
- Correspondence
Dr. Calabrese calabresem{at}hotmail.it
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hemiplegic Migraine Associated With PRRT2 Variations A Clinical and Genetic Study
Dr. Robert Shapiro and Dr. Amynah Pradhan
Related Articles
- No related articles found.